REG - RTW Biotech Opp. - Artiva Biotherapeutics prices IPO at $167 million

RTW Biotech OpportunitiesAnnouncement

22/07/2024 12:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240722:nRSV3014Xa&default-theme=true

RNS Number : 3014X  RTW Biotech Opportunities Ltd  22 July 2024

LEI: 549300Q7EXQQH6KF7Z84

22 July 2024

RTW Biotech Opportunities Ltd

Portfolio Company Update: Artiva Biotherapeutics prices IPO at $167 million

RTW Biotech Opportunities Ltd (the "Company"), a London Stock Exchange-listed
investment company focused on identifying transformative assets with high
growth potential across the life sciences sector, is pleased to note the
announcement by Artiva Biotherapeutics ("Artiva") regarding its pricing of a
$116 million initial public offering ("IPO"). Artiva will trade on Nasdaq
Global Market under the ticker "ARTV".

Artiva's IPO raised $167 million by offering 13,920,000 shares at $12.00 per
share. The shares finished flat on the first day of trading. As at 30 June
2024, Artiva represented 0.13% of the Company's NAV.

Artiva is a clinical-stage biotechnology company focused on developing natural
killer (NK) cell-based therapies whose mission is to develop effective, safe,
and accessible cell therapies for patients with devastating autoimmune
diseases and cancers. The Company initially invested in Artiva's Series B
round in February 2021.

Chris Liu, PhD, Senior Research Analyst at the Investment Manager said,
"Artiva Biotherapeutics is diligently advancing its lead allogeneic natural
killer (NK) cell therapy, AlloNK, through several clinical trials. Currently,
AlloNK is undergoing a phase 1 trial for lupus nephritis and participating in
a basket study across various autoimmune indications. The recent IPO
underscores the significant potential impact of this groundbreaking therapy."

The full text of Artiva's announcement can be accessed on its website at:
https://artivabio.com/
(https://investors.artivabio.com/News-and-Events/news/news-details/2024/Artiva-Biotherapeutics-Announces-Pricing-of-Upsized-167.0-Million-Initial-Public-Offering/default.aspx)
.

 For Further Information

 RTW Investments, LP                                      +44 20 7959 6361
 Woody Stileman, Managing Director, Business Development  biotechopportunities@rtwfunds.com (mailto:biotechopportunities@rtwfunds.com)

 Krisha McCune, Director, Investor Relations

 Buchanan (PR & Communications Adviser)                   +44 20 7466 5107

 Charles Ryland

 Henry Wilson

 George Beale

 Deutsche Numis (Joint Corporate Broker)                  +44 20 7260 1000

 Freddie Barnfield

 Nathan Brown
 Euan Brown
 BofA Securities (Joint Corporate Broker)                 +44 20 7628 1000
 Edward Peel
 Alex Penney
 Cadarn Capital (Distribution & IR Partner)                +44 73 6888 3211
 David Harris
 Elysium Fund Management Limited                           +44 14 8181 0100

 Joanna Duquemin Nicolle, Chief Executive Officer

 Sadie Morrison, Managing Director

 Morgan Stanley Fund Services USA LLC                     +1 914 225 8885

About Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW & RTWG) is an investment fund
focused on identifying transformative assets with high growth potential across
the biopharmaceutical and medical technology sectors. Driven by a long-term
approach to support innovative businesses, RTW Biotech Opportunities Ltd
invests in companies developing next-generation therapies and technologies
that can significantly improve patients' lives. RTW Biotech Opportunities Ltd
is managed by RTW Investments, LP, a leading healthcare-focused
entrepreneurial investment firm with deep scientific expertise and a strong
track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd
(https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/)  for more
information.

***********

The information in this announcement may include forward-looking statements,
which are based on the current expectations and projections about future
events, and in certain cases can be identified by the use of terms such as
"may", "will", "should", "expect", "anticipate", "project", "estimate",
"intend", "continue", "target", "believe" (or the negatives thereon) or other
variations thereon or comparable terminology. These forward-looking
statements, as well as those included in any related materials, are subject to
risks, uncertainties and assumptions about the Company and/or its underlying
investments, including, among other things, the development of the applicable
entity's business, trends in its operating industry, expected use of financing
proceeds and future capital expenditures and acquisitions. In light of these
risks, uncertainties and assumptions, the events in the forward-looking
statements may not occur.

The information contained in this announcement is given at the date of its
publication (unless otherwise marked). No reliance may be placed for any
purpose whatsoever on the information or opinions contained in this
announcement or on its completeness, accuracy or fairness.

***********

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBLLFLZDLZBBB